A regulatory breakthrough brings new possibilities for medical diagnosis.
BILBAO
Spanish health technology company Legit.Health has announced a significant regulatory milestone after securing European Medical Device Regulation (MDR) certification for its artificial intelligence system designed to assist dermatological diagnosis. The Bilbao-based company’s software can analyze clinical photographs and help healthcare professionals identify signs associated with more than 300 skin conditions, including melanoma, psoriasis and acne. The development represents another step toward integrating artificial intelligence into routine medical practice, although its potential impact on hospital waiting times remains to be demonstrated.
The certification, issued by notified body BSI on September 15 and publicly announced on November 19, 2026, classifies the technology as a Class IIb medical device under European Regulation 2017/745. This regulatory framework establishes requirements for medical device safety, clinical performance, risk management and ongoing surveillance. Unlike experimental applications developed without a regulated medical purpose, the certified software has undergone a formal conformity assessment for its intended clinical use.
The technology operates through an image-based assessment process. A healthcare professional captures a photograph of a suspected skin condition, which is processed by computer vision algorithms to generate a ranked list of possible diagnoses. The system also evaluates measurable clinical features, including the extent and intensity of visible symptoms, allowing physicians to monitor disease progression and treatment response. Its outputs support clinical judgment rather than establish a definitive diagnosis independently.
The announcement comes as Spain continues to confront substantial delays in specialist healthcare. According to the Spanish Ministry of Health’s figures for December 2025, patients waited an average of 127 days for an initial dermatology consultation, compared with 102 days across hospital outpatient specialties. Such delays highlight the importance of improving referral processes, particularly when suspicious lesions require timely specialist assessment.
Legit.Health argues that its platform could help primary care physicians identify cases requiring urgent dermatological attention while allowing less serious conditions to follow appropriate monitoring pathways. The company also reports clinical research involving more than 700 patients and publications evaluating aspects of its technology. However, neither certification nor evidence of diagnostic assistance establishes that the system has already reduced waiting lists across healthcare networks.
The distinction between regulatory compliance and measurable clinical outcomes is particularly important in medical artificial intelligence. Algorithms may perform well under controlled evaluation conditions while encountering additional challenges in everyday clinical environments, including differences in image quality, disease prevalence, patient characteristics and professional interpretation. Independent assessment of diagnostic accuracy, false-negative results and performance across different skin types will remain essential as deployment expands.
Legit.Health already collaborates with public healthcare services in Asturias and Aragón, alongside private-sector organizations in Spain and Poland. Its expansion reflects growing institutional interest in technologies that could improve healthcare efficiency without transferring final clinical responsibility from physicians to automated systems. The company’s certification under Spain’s National Security Framework also addresses information-security requirements relevant to processing sensitive medical data.
More broadly, the development illustrates a shift in how artificial intelligence is entering European healthcare. The central issue is no longer whether software can recognize patterns in medical images, but whether these capabilities can be implemented safely, equitably and effectively within complex clinical systems. Regulatory certification provides an important foundation, yet meaningful improvements in patient access will depend on independent clinical evidence and measurable results after deployment.
For patients facing months of uncertainty before receiving specialist attention, the promise of faster evaluation is significant. Whether that promise becomes a demonstrable improvement in healthcare delivery will depend on how responsibly the technology is integrated into medical practice.
Where Innovation Meets Responsibility.